| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.UROLOGY.2006.10.022 |
| P8608 | Fatcat ID | release_2u7buetrvjg77hrvzsqmhianvu |
| P698 | PubMed publication ID | 17169636 |
| P50 | author | Donna Ankerst | Q58241772 |
| P2093 | author name string | Javier Hernandez | |
| Edith Canby-Hagino | |||
| Ian M Thompson | |||
| Dipen J Parekh | |||
| Robin J Leach | |||
| Dean A Troyer | |||
| Timothy Brand | |||
| Betsy A Higgins | |||
| P2860 | cites work | Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter | Q34323096 |
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer | Q35065401 | ||
| Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. | Q39519228 | ||
| Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL | Q39665630 | ||
| Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower | Q39722492 | ||
| Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial | Q39752227 | ||
| African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram | Q39768780 | ||
| Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population | Q40605923 | ||
| Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting | Q44910479 | ||
| A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer | Q48030260 | ||
| Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium | Q77355215 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1152-1155 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population | |
| P478 | volume | 68 |
| Q39377009 | A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore |
| Q37184507 | Algorithms, nomograms and the detection of indolent prostate cancer |
| Q27304922 | Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer |
| Q34398521 | Belief in numbers: When and why women disbelieve tailored breast cancer risk statistics |
| Q37486280 | Cancer communication: status and future directions |
| Q34104562 | Critical review of prostate cancer predictive tools |
| Q38268839 | Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis |
| Q95609907 | Editorial comment |
| Q36739758 | Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| Q42932905 | Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. |
| Q89029851 | External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study |
| Q37074118 | External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort. |
| Q37299250 | ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males |
| Q46397195 | ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males |
| Q35940811 | Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators |
| Q37279076 | Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator |
| Q37310024 | Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations |
| Q38849399 | KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach |
| Q40461863 | Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. |
| Q48513543 | Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower |
| Q92694867 | Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population |
| Q35924515 | Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone |
| Q35292878 | Prediction models in cancer care |
| Q34586836 | Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America |
| Q37252155 | Prospective evaluation of operating characteristics of prostate cancer detection biomarkers |
| Q35996067 | Prostate cancer risk prediction in a urology clinic in Mexico |
| Q57137856 | Prostate cancer screening |
| Q37763709 | Prostate cancer screening 2010: updated recommendations from the American Cancer Society |
| Q58799069 | Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort |
| Q35840271 | Prostate-specific antigen in the early detection of prostate cancer |
| Q37573519 | Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype? |
| Q37120274 | Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. |
| Q39003646 | Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. |
| Q37662874 | Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial |
| Q37963657 | Risk-based prostate cancer screening. |
| Q38093463 | Risk-based prostate cancer screening: who and how? |
| Q37526808 | Techniques and predictive models to improve prostate cancer detection |
| Q37414994 | The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study |
| Q37075718 | The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome |
| Q24658011 | The benefits and risks of testosterone replacement therapy: a review |
| Q37793100 | The evolving role of familial history for prostate cancer |
| Q37001612 | The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator |
| Q28749313 | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group |
| Q36185925 | The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting |
| Q40037072 | The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study |
| Q59575001 | Translational Risk Models |
| Q37025404 | Updating risk prediction tools: a case study in prostate cancer |
| Q34604979 | Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline |
| Q48526825 | Utility of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. |
| Q39904254 | Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection |
| Q37284258 | Validation of biomarker-based risk prediction models |
| Q83598904 | [The new biomarkers of prostate cancer] |
Search more.